Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by josameyeron Dec 11, 2010 8:21am

520 Views

Post# 17833239

RE: What Is up with Brigus?

Last trade for Brigus on the American Exchange yesterday was at 19.16 hrs at $ 1.84. Final total tally was 2 million 362 thousand 100 shares.Draw your own conclusions. I maintain the question, whats up with Brigus.. In my opinion given the time when the stock started to move in volume and price on both exchanges was nice but strange. DYODD. Cheers Josa.

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features